General Information
Amgen NAFLD 20200001
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG609 in Subjects with Non-Alcoholic Fatty Liver Disease.
| Protocol | 20200001 |
|---|---|
| Identifier | |
| UID | d869ad13-d511-4d04-80af-b210d46acce1 |
| Status | Done - Archived |
| Phase | 1 |
| Category | Fatty Liver / Adult |
| Launch Year | 2022 |
| NCT Number | NCT04857606 |
| Created | 2022-04-27 16:54 |
| Last Updated | 2024-04-02 20:13 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | 2022-12-05 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2022-11-03 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2023-12-07 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | - | No | |
| Coordinator | Gallardo, Michael | MGallardo | No |
| Regulatory | Ramirez, Claudia | CRamirez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Amgen |
|---|---|
| Division | Amgen |
| Team | Amgen |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
